Screening for Mild Cognitive Impairment in Parkinson’s Disease: Comparison of the Italian Versions of Three Neuropsychological Tests

Table 1

Demographic and clinical characteristics of the patients.

Pt	Sex	Age (y)	School (y)	Duration (y)	H-Y (1–5)	Treatment and daily dosage	Depression (yes/no)
1	F	44	12	5	1	PRX 4.5 mg, RAS 1 mg	No
2	M	46	8	15	3	LD 600 mg, APO 36 mg, PRX 3 mg	Yes
3	M	51	13	10	2.5	LD 1150 mg	No
4	F	52	11	14	2	APO 84 mg, CAB 9 mg	No
5	F	56	13	11	2.5	LD 500 mg, APO 48 mg, PRX 4.5 mg	Yes
6	F	57	13	10	2	LD 600 mg, APO 52 mg	No
7	M	60	12	8	3	LD 500 mg	Yes
8	M	60	8	20	3	LD 750 mg	Yes
9	M	61	8	5	1	RAS 1 mg	Yes
10	M	61	13	21	2.5	LD 950 mg	No
11	F	63	10	4	1.5	PRX 3 mg	Yes
12	F	64	5	2	1.5	LD 400 mg	Yes
13	F	65	5	10	2.5	LD 700 mg, PRX 1.5 mg, RAS 1 mg	No
14	F	67	13	10	2	LD 1000 mg, PRX 4.5 mg	No
15	M	67	10	5	1	LD 400 mg	No
16	M	67	8	1	1	None	Yes
17	M	68	8	3	1.5	LD 400 mg	Yes
18	M	68	8	22	2.5	LD 975 mg	Yes
19	M	68	10	21	3	LD 1250 mg	Yes
20	M	68	8	23	2.5	LD 1150 mg	No
21	M	69	8	24	3	LD 950 mg	Yes
22	M	69	5	4	3	LD 850 mg	No
23	M	70	10	24	4	LD 1200 mg	Yes
24	F	70	3	10	1.5	LD 800 mg	No
25	M	72	8	4	1	LD 350 mg, ROP 8 mg	No
26	F	72	12	12	2.5	LD 550 mg, APO 42 mg	No
27	M	72	8	12	2.5	LD 1250 mg	No
28	F	73	5	5	1	LD 250 mg, SEL 10 mg	No
29	M	73	13	7	3	LD 1250 mg, ROT 10 mg	No
30	M	74	8	4	3	LD 700 mg, PRX 3 mg	No
31	M	75	8	6	3	LD 600 mg, ROP 16 mg	No
32	M	75	5	3	1	ROP 16 mg, SEL 10 mg	No
33	M	75	5	20	3	LD 1100 mg, ROP 12 mg	No
34	M	75	5	10	2.5	LD 800 mg, PRX 4.5 mg	Yes
35	F	75	5	5	2	LD 300 mg, ROP 16 mg	No
36	M	76	8	20	2.5	LD 1150 mg, PRX 3 mg	No
37	M	76	6	10	2	LD 900 mg, PRX 3 mg	No
38	M	76	5	25	3	LD 1250 mg	No
39	F	76	8	8	2	LD 1000 mg	Yes
40	M	76	13	11	2	LD 750 mg	Yes
41	F	79	5	4	2	LD 300 mg	No
42	F	83	5	4	2	LD 500 mg	Yes
43	F	88	4	1	1.5	LD 400 mg	No
Average		68.2	8.3	10.5	2.2
SD		9.3	3.0	7.3	0.8

Pt: patient; school: education (years); duration: disease duration (years); H-Y: Modified Hoehn and Yahr Staging Scale (range 1–5); SD: standard deviation; APO: apomorphine; CAB: cabergoline; LD: levodopa (dosage corrected according to the eventual use of COMT-inhibitors); PRX: pramipexole; RAS: rasagiline; ROP: ropinirole; ROT: rotigotine; SEL: selegiline.